Thermo Fisher Scientific launches Efficient-Pro Medium (+) Insulin for enhanced bioprocessing performance

Thermo Fisher Scientifichas launched its Gibco™ Efficient-Pro™ Medium (+) Insulin, a next-generation medium designed to increase titers to maximize productivity and elevate the performance of insulin-dependent CHO cell lines. Efficient-Pro Medium (+) Insulin is the latest addition to Thermo Fisher’s existing Efficient-Pro medium and feed system, designed to provide optimized growth and productivity for insulin-dependent CHO cell lines, with streamlined workflow and handling.

As the biologics industry pushes for faster development timelines, reduced cost-of-goods, and greater supply chain agility, Efficient-Pro Medium (+) Insulin provides a future-ready solution. It is designed to eliminate the need for manual insulin supplementation, and for robust quality systems that help support supply assurance and confidence in the delivery of consistent, high-quality products.

Efficient-Pro Medium (+) Insulin offers improved protein yield and optimized productivity for insulin-dependent CHO cell lines commonly used in monoclonal antibody and biosimilar production, while also simplifying the preparation process and logistics.

Biopharma manufacturers, biotechnology companies, and contract development and manufacturing organizations (CDMOs) can benefit from:

• Higher protein titers – the solution offers up to 61% higher protein titers compared to other alternatives
• High viable cell densities and robust growth, all without compromising product quality
• Compatibility with a broad range of insulin-dependent CHO cell lines and increased flexibility through a variety of formats and packaging configurations
• Dry format compatibility via Thermo Fisher’s Gibco™ Advanced Granulation Technology™ (AGT™) dry media, enabling ease of use, rapid reconstitution and scalability
• Animal origin–free (AOF) formulation that reduces process variability and eases regulatory complexity, helping customers achieve dependable results with greater peace of mind

For protein therapeutic developers (e.g., mAb, bispecific, Fc-fusion proteins, etc.), Efficient-Pro Medium (+) Insulin simplifies process development by providing consistent, high-performance growth and production conditions with reduced variability.

“Our announcement represents a significant enhancement in bioprocessing technology,” said Sara Henneman, vice president and general manager of Thermo Fisher Scientific’s cell culture and cell therapy business. “By integrating our AGT format and ensuring an AOF formulation, we are addressing key industry challenges and providing our customers with a reliable, high-performance solution. Efficient-Pro Medium (+) Insulin underscores our dedication to innovation and our mission to support the development of groundbreaking therapies that improve patient outcomes worldwide.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>